In the past week, ABCL stock has gone down by -8.45%, with a monthly decline of -2.17% and a quarterly surge of 2.65%. The volatility ratio for the week is 6.08%, and the volatility levels for the last 30 days are 6.25% for AbCellera Biologics Inc The simple moving average for the past 20 days is -2.78% for ABCL’s stock, with a -21.96% simple moving average for the past 200 days.
Is It Worth Investing in AbCellera Biologics Inc (NASDAQ: ABCL) Right Now?
Additionally, the 36-month beta value for ABCL is 0.35. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABCL is 211.32M and currently, short sellers hold a 7.87% ratio of that float. The average trading volume of ABCL on November 20, 2024 was 2.20M shares.
ABCL) stock’s latest price update
AbCellera Biologics Inc (NASDAQ: ABCL)’s stock price has gone rise by 2.26 in comparison to its previous close of 2.65, however, the company has experienced a -8.45% decrease in its stock price over the last five trading days. businesswire.com reported 2024-11-07 that VANCOUVER, British Columbia–(BUSINESS WIRE)—- $ABCL–AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024.
Analysts’ Opinion of ABCL
The Benchmark Company, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $9. The rating they have provided for ABCL stocks is “Buy” according to the report published on February 22nd, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to ABCL, setting the target price at $6 in the report published on December 05th of the previous year.
ABCL Trading at 0.94% from the 50-Day Moving Average
After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.24% of loss for the given period.
Volatility was left at 6.25%, however, over the last 30 days, the volatility rate increased by 6.08%, as shares sank -4.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.04% upper at present.
During the last 5 trading sessions, ABCL fell by -8.45%, which changed the moving average for the period of 200-days by -45.25% in comparison to the 20-day moving average, which settled at $2.79. In addition, AbCellera Biologics Inc saw -52.54% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABCL
Current profitability levels for the company are sitting at:
- -9.35 for the present operating margin
- -1.8 for the gross margin
The net margin for AbCellera Biologics Inc stands at -5.33. The total capital return value is set at -0.23. Equity return is now at value -15.55, with -12.10 for asset returns.
Currently, EBITDA for the company is -192.16 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 22.61. The receivables turnover for the company is 0.52for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.34.
Conclusion
In conclusion, AbCellera Biologics Inc (ABCL) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
